Board of Directors
Dr Miroslav Reljanovic
Dr Miroslav Reljanovic initially worked for 15 years as a physician in the Vuk Vrhovac Institute for diabetes, endocrinology and metabolic diseases in Zagreb (a WHO Collaborating Centre). In addition to the background in epidemiology, he has been a qualified neurologist since 1989. During this period, he was a clinical investigator in several Phase 2 and 3 studies in the field of diabetic neuropathy and was also consulting to several pharma companies.
In 1997, Miro set up Ergomed, Croatia's first CRO and he introduced the novel Study Site Coordination model as an intrinsic part of the operation. In 2001, he established Ergomed Clinical Research Ltd in the UK as the main business and contracting company for the Ergomed Group. Since its inception, Dr Reljanovic has successfully grown Ergomed into an organization with around 100 employees, with offices in the UK, Germany, Croatia, Poland, Spain, Serbia, Russia, Dubai and the USA. During this period - Ergomed has established long term relationships with an international range of biotech and pharmaceutical companies. Miro has also successfully introduced a novel co-development business model and Ergomed has already completed two transactions with one European and another North American listed biopharma company.
Dr Elliot Brown
Dr Elliot Brown worked for several years as a GP, then spent 10 years in senior positions in the pharma industry in pharmacovigilance and in medical services. He was a senior medical assessor for 5 years at the UK MHRA and was their representative on the EMEA's Pharmacovigilance Working Party. He has been a member of ICH and CIOMS expert working groups on MedDRA, WHO's signal review panel and has published extensively on pharmacovigilance. For the last 10 years, Elliot has headed Elliot Brown Consulting, an international firm of consultants specialising in Pharmacovigilance, risk management, regulatory compliance and training. He is well known internationally as a trainer and speaker and has extensive experience ranging from writing Risk Management Plans, chairing Data Safety Monitoring Boards and Pharmacovigilance auditing through to assisting pharma companies large and small in managing new serious concerns with product safety.
Stephen Douglas
Stephen Douglas is a biologist who joined the pharma industry in 1978 and has worked with medium to large pharmaceutical companies. His initial 3 years were in sales and marketing prior to a move to clinical development for Phase III and Phase IV clinical trials, subsequently including all phases from I to IV. He has been project director for small studies and large multinational safety studies. For over 15 years he has specialized in Pharmacovigilance. For the last ten years he has worked in senior roles within the Clinical Research Organization (CRO) sector including eight years with PAREXEL. As a consultant he has specialized in the development of compliant Pharmacovigilance systems, including Pharmacovigilance and risk management planning at the time of application for marketing through to supporting inspection readiness, auditing and training in the post-marketing environment. As a contracted Qualified Person he has been directly responsible to EEA regulatory authorities as the single point of contact for safety issues for marketed products.
Neil Clark
Neil Clark studied life sciences at university before training as an accountant with Coopers & Lybrand - now PWC. Neil worked in their Cambridge office for ten years on a variety of local, national and international assignments in audit, corporate finance and consultancy. Neil also worked abroad in Australia and Europe. On leaving in 1997 he joined CeNeS Pharmaceuticals and was Finance Director and then Chief Executive of CeNeS which was listed on London Aim market. CeNeS was a CNS focused biotechnology company that was sold in June 2008 to Paion. On completing the sale Neil left CeNeS and has been working as a consultant until joining ERGOMED as Chief Finance Officer in January 2009.
For more information contact PrimeVigilance today